Summary

• Page properties (1 modified, 0 added, 0 removed)

Details

Page properties

Content

...	...	@@ -2,12 +2,10 @@
2	2	{{toc/}}
3	3	{{/box}}
4	4
5		-= Paragraph 1 =
	5	+= Overview =
6	6
7		-==== Overview ====
	7	+Rocket Pharmaceuticals, Ltd. is a multi-platform biotechnology company focused on the development of first-in-class gene therapies for rare and devastating pediatric diseases. Rocket Pharma has two lentiviral virus (“LVV”) programs currently undergoing clinical testing targeting Fanconi Anemia (“FA”), a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells, and three additional LVV programs targeting other rare genetic diseases. In addition, Rocket Pharma has an adeno-associated virus (“AAV”) program for which it expects to file an investigational new drug (“IND”) application in the next 12 months, which will permit the commencement of human clinical studies thereafter. Rocket Pharma has full global commercialization and development rights to all of its product candidates under royalty-bearing license agreements, with the exception of the CRISPR/Cas9 development program (described below) for which Rocket Pharma currently only has development rights.{{footnote}}https://fintel.io/doc/sec-rckt-rocket-pharmaceuticals-10k-annual-report-2018-march-07-18040{{/footnote}}
8	8
9		-Rocket Pharmaceuticals, Ltd. is a multi-platform biotechnology company focused on the development of first-in-class gene therapies for rare and devastating pediatric diseases. Rocket Pharma has two lentiviral virus (“LVV”) programs currently undergoing clinical testing targeting Fanconi Anemia (“FA”), a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells, and three additional LVV programs targeting other rare genetic diseases. In addition, Rocket Pharma has an adeno-associated virus (“AAV”) program for which it expects to file an investigational new drug (“IND”) application in the next 12 months, which will permit the commencement of human clinical studies thereafter. Rocket Pharma has full global commercialization and development rights to all of its product candidates under royalty-bearing license agreements, with the exception of the CRISPR/Cas9 development program (described below) for which Rocket Pharma currently only has development rights.
10		-
11	11	Rocket Pharma’s two leading LVV and AAV technology platforms are each being designed in collaboration with leading academic and industry partners. Through its gene therapy platforms, Rocket aims to restore normal cellular function by modifying the defective genes that cause each of the targeted disorders.
12	12
13	13	On January 4, 2018, Inotek Pharmaceuticals Corporation (“Inotek”) and Rocket Pharma completed a business combination in accordance with the terms of the Agreement and Plan of Merger and Reorganization (the “Merger Agreement”), dated as of September 12, 2017, by and among Inotek, Rome Merger Sub, a wholly owned subsidiary of Inotek (“Merger Sub”) and Rocket Pharma, pursuant to which Merger Sub merged with and into Rocket Pharma, with Rocket Pharma surviving as a wholly owned subsidiary of Inotek. This transaction is referred to as “the Merger.” Immediately following the Merger, Inotek changed its name to Rocket Pharmaceuticals, Inc. (“Rocket”).
...	...	@@ -16,7 +16,7 @@
16	16
17	17	In connection with the closing of the Merger, Rocket’s common stock began trading on The NASDAQ Global Market under the ticker symbol “RCKT” on January 5, 2018. The accompanying financial statements do not give effect to the Merger.
18	18
19		-==== Risks and Liquidity ====
	17	+= Risks and Liquidity =
20	20
21	21	The Company has not generated any revenue and has incurred losses since inception. Operations of the Company are subject to certain risks and uncertainties, including, among others, uncertainty of drug candidate development, technological uncertainty, uncertainty regarding patents and proprietary rights, having no commercial manufacturing experience, marketing or sales capability or experience, dependency on key personnel, compliance with government regulations and the need to obtain additional financing. Drug candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance-reporting capabilities.
22	22
...	...	@@ -26,11 +26,11 @@
26	26
27	27	In the longer term, the future viability of the Company is dependent on its ability to generate cash from operating activities or to raise additional capital to finance its operations. The Company’s failure to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies.
28	28
29		-==== Property and Equipment ====
	27	+= Property and Equipment =
30	30
31	31	Property and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over the useful life of the asset. The estimated useful lives are three to five years. Expenditures for repairs and maintenance of assets are charged to expense as incurred. Upon retirement or sale, the cost and related accumulated depreciation of assets disposed of are removed from the accounts and any resulting gain or loss is included in loss from operations. If the carrying amount of the assets or asset group is not recoverable on an undiscounted cash flow basis, impairment is recognized to the extent that the carrying value exceeds its fair value. No impairment losses were recognized during the years ended December 31, 2017 and 2016.
32	32
33		-==== Agreements Related to Intellectual Property and Manufacturing Agreements ====
	31	+== Agreements Related to Intellectual Property and Manufacturing Agreements ==
34	34
35	35	The Company has entered into various license and research and collaboration arrangements. The transactions principally resulted in the acquisition of intellectual property which is in the pre-clinical phase and have not been tested for safety or feasibility. In all cases, the Company did not acquire tangible assets, processes, protocols or operating systems. The Company expenses the acquired intellectual property assets as of the acquisition date on the basis that the cost of intangible assets purchased from others for use in research and development activities, has no alternative future uses.
36	36
...	...	@@ -118,6 +118,10 @@
118	118
119	119	As of December 31, 2017, the Company had total remaining commitments under these agreements of $1,331.
120	120
121		-==== Manufacturing Agreements ====
	119	+= Manufacturing Agreements =
122	122
123	123	During the year ended December 31, 2017, the Company entered into non-cancelable commitments with multiple contract manufacturers. Total remaining commitments under these contracts were $1,296 at December 31, 2017.
	122	+
	123	+= References =
	124	+
	125	+{{putFootnotes/}}